Synopsis : Mycobacterium avium and Mycobacterium intracellulare , collectively known as the M. avium complex, are the most common causes of nontuberculous mycobaterial lung disease. Treatment of M. avium complex lung disease is challenging, as it requires patients to adhere to a multidrug regimen ...
Interstitial lung diseaseMycobacterium avium complexSystemic sclerosisWe describe a case of a 65-year-old male with recently diagnosed diffuse cutaneous systemic sclerosis associated with usual interstitial pneumonia and pulmonary hypertension. Patient presented to the emergency department complaining of low-...
Joe Bates described macrolide therapy for Mycobacterium avium complex (MAC) lung disease as "the most important progress made in more than 30 years in treating MAC pulmonary disease" (1). Unfortunately, that degree of initial enthusiasm has been tempered somewhat with subsequent experience. There ...
Management of Mycobacterium avium complex (MAC) lung disease is complicated, frequently unsuccessful, and frustrating to patients and clinicians. The initial treatment effort may not be directed solely at MAC infection, rather it is often initiating airway clearance measures for bronchiectasis. The next...
Computed tomographic abnormalities in Mycobacterium avium complex lung disease include the mosaic pat- tern of reduced lung attenuation. Can Assoc Radiol J 2000; 51: 3 - 102Maycher, B., O´Connor, R., & Long, R. 2000. Computed tomographic abnormalities in Mycobacterium avium complex lung ...
Mycobacterium avium/Mycobacterium intracellularenontuberculous mycobacteriatype 2 pneumocyteThe lack of useful biomarkers reflecting the disease state limits the management of Mycobacterium avium complex lung disease (MAC-LD). We clarified the associations between serum KL-6 level, disease progression and ...
(HealthDay)—Arikayce has been approved by the U.S. Food and Drug Administration to treat lung disease caused by Mycobacterium avium complex (MAC) bacteria among people who don't respond to conventional therapies, the FDA said in a news release.
Mycobacterium avium intracellulare complex (MAC) infection is a common cause of significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients. It usually presents as a systemic disease process. Endobronchial disease secondary to MAC is distinctly rare and can be a manifes...
Mycobacterium avium complex lung disease is an increasingly common and chronically debilitating problem. Several host traits have been suggested or confirmed as risk factors. Potential environmental and behavioral risk factors have also been proposed. Few have been evaluated in comparative studies.To determ...
(FDA) approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional tre...